Amgen Presents Data on Vectibix/Chemo Efficacy in Wild-Type KRAS Colorectal Cancer Patients
January 27, 2010
Amgen Presents Data on Vectibix/Chemo Efficacy in Wild-Type KRAS Colorectal Cancer Patients
"Our data reinforce the importance of the KRAS mutation as a predictive biomarker for responsiveness to Vectibix therapy," said Roger Perlmutter, Amgen's executive vice president of research and development.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen Enters Companion Dx Market with Approval of KRAS Test Kit for Erbitux; LDT Impact Unknown
July 11, 2012 / Pharmacogenomics Reporter - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - Amgen Lays Out Timeline for KRAS Mutation Studies to Dispel Perceptions of Unethical Rx Development
February 24, 2010 / Pharmacogenomics Reporter - FDA Update to Erbitux, Vectibix Labels Encourages Rx/Dx Co-development, Industry Expert Says
July 22, 2009 / Pharmacogenomics Reporter - Investment Bank Reports Advantage of CLIA Labs in Driving Adoption of OncotypeDX
April 8, 2009 / Pharmacogenomics Reporter